Precision BioSciences Presents New Preclinical Data Supporting the Advancement of PBGENE-DMD into Clinic at the American Society of Gene & Cell Therapy 2026 Annual Meeting
Go back to Precision BioSciences Presents New Preclinical Data Supporting the Advancement of PBGENE-DMD into Clinic at the American Society of Gene & Cell Therapy 2026 Annual Meeting| (NASDAQ: DTIL) | Delayed: 7.06 +0.25 (3.67%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $6.81 | 52 Week High | $ | |||
| Open | $6.95 | 52 Week Low | $ | |||
| Day High | $7.20 | P/E | N/A | |||
| Day Low | $6.88 | EPS | $ | |||
| Volume | 284,174 | |||||
